Summary.-Acute leukaemias stimulated proliferative and cell-mediated cytotoxic (CMC) responses in vitro in normal (unprimed) 
non-lymphoid mononuclear cells has been the subject of intense investigation (reviewed by Herberman et al., 1979; Saksela et al., 1979; Santoli & Koprowski, 1979) there is general agreement that human NK cells do not express cell-, surface immunoglobulin, or C3 receptors, but do have Fc receptors (Pross & Jondal 1975; Nelson et al., West et al., 1977; Bakacs et al., 1977) and are non-adherent to plastic surfaces and nylon fibres (Santoli & Koprowski, 1979; Herberman et al., 1979) .
NK cells can be detected by their capacity to lyse cultured cell-lines (CCL) of malignant origin, and speculation has thus focused upon the role that NK cells might play in the prevention of tumourcell growth in vivo IHerberman & Holden, 1978; Santoli & Koprowski, 1979) . However, it has yet to be shown conclusively that NK cells are responsible for the lysis of fresh human leukaemia cells, even though spontaneous CMC against autologous acute leukaemias has been reported (Herberman et al., 1974) . In this respect procedures for the specific purification of NK cells, such as those based upon absorption on targetcell monolayers (Jensen et al., 1979) are likely to be useful.
Stimulation of human lymphocytes in mixed leucocyte cultures by a variety of cell types leads to augmented CMC on cultured cell lines (Callewaert et al., 1975 (Callewaert et al., , 1977 Ortaldo & Bonnard, 1977) . This CMC can be distinguished in its kinetic characteristics from allospecific T-cell cytotoxicity and may be mediated by NK or activated NK cells (Seeley & (Golub, 1978) . Lymphocytes from acute leukaemia patients in remission, stimulated in vitro with allogeneic acute leukaemia cells, develop CMC to fresh leukaemias only when patients have been immunized in vivo with leukaemiacell immunotherapy (Taylor et al., 1979) . The purpose of this study was to assess the capacity of different leukaemias to amplify in vitro or block CMC in normal and primed lymphocytes on leukaemia and CCL targets as a means of determining the relationship between anti-leukaemic CMC and CMC on cell lines.
MATERIALS AND METHODS

Preparation of lynmphocytes
Blood donors included normal individuals and acute leukaemia patients in remission. Remission induction and immunotherapy of the leukaemia patients have been described (Taylor et al., 1979) . Defibrinated blood was diluted 1:1 with Hanks' Balanced Salt Solution (HBSS) and separated on lymphocyteseparation medium (LSM, sp. gr. 1077, Flow Laboratories, frvine, Scotland). Lymphocytes obtained at the LSM-plasma interface were diluted with Eagle's medium + foetal calf serum (MEM-FCS) and sedimented by centrifugation. The lymphocytes were resuspended in MEM-FCS, washed and resuspended in RPMI-1640 containing 10% heat-inactivated AB serum (1640-AB).
Cultured cell lines (CCL)
The CCI used in this study were K562, an erythroleukaemia (Lozzio & Lozzio, 1975; Andersson et al., 1979) , CCRF-CEM and MOLT 4 (T-cell leukaemias), Daudi (Burkitt's lymphoma) AA-F, T51 and PRIESS (B lymphoblastoid cells). They were cultured in 500ml glass bottles in -100 ml of 1640-FCS (10%) and antibiotics at 37TC in a 950o air/ 500 CO2 gas mixture. Media were changed twice weekly, and only actively growing cells with > 9500 viability were used as targets.
Leukaemia cells
The procurement of leukaemia cells, their separation from peripheral blood, freezing and storage have been described elsewhere (Taylor et al., 1979) . The cells are denoted by their laboratory codes and are of the following diagnostic types: AL-45 (AML), AL-47X (ALL), AL-48 (AMoL), AL-49 (AMML), AL-51 (AML), .
Abbreviations: AML = acute myeloblastic leukaemia; AMoL = acute monoblastic leukaemia; ALL = acute lymphoblastic leukaemia; AMML = acute myelomonocytic leukaemia; AL=acute leukaemia.
Nylon -columnn separation
Lymphocytes were separated into nylonadherent and non-adherent cells by passage through nylon columns, according to the method of Julius et al. (1973) . Briefly, washed nylon from a Fenwal Leucopak (Travenol Laboratories) was packed to the lml mark of a 5ml syringe and incubated with 5 ml of 1640-HEPES for 30 min at 37TC. One ml of lymphocyte suspension (2-4 x 107 cells) was added and the column incubated for 30 min at 37TC. The non-adhering lymphocytes were washed through with warm 1640-HEPES-FCS and collected in a final volume of 10 ml. They were sedimented by centrifugation and resuspended in 1640-AB for culture. ulixed leucocyte cult ures Unfiltered or nylon-non-adherent lymphocytes were adjusted to 2 x 106/ml for use as responding cells. Stimulating cells were CCL, leukaemia cells or allogeneic lymphocytes, treated either with Mitomycin C (MC, Sigma Chemical Co., Kingston-upon-Thames) at a concentration of 50-100 ,ug/107 cells for 30 min at 37°C, or with 60 Gy from a 137CS source. Stimulating cells were washed 3 x after MC treatment, but not after irradiation, and adjusted to 2 x 106/ml. Equal volumes (2 ml) of responding and stimulating cells were mixed in round-bottomed plastic tissueculture tubes (Sterilin, Teddington). The tubes were gassed with 95%O air/500 C02, transferred to a humidified Gas-Pak 150 jar (Beckton-Dickinson, Wembley) and incubated at 37°C for 6 days (day of culture= Day 0). Replicate cultures were then harvested and pooled, washed once in 1640-HEPES-FCS and adjusted to cell concentrations appropriate for CMC assays.
Cell-mediated cytotoxicity Taryet cells-.These included PHA-transformed lymphocytes, CCL and leukaemia cells. Normal lymphocytes (106/ml) were transformed by incubation for 3 days with PHA (Difco PHA-P, 10 ,ul of a 1/100 diluted stock solution/ml culture). Leukaemia cells and CCL were prepared as described previously (Taylor et al., 1979) . All target cells were labelled with 200 ltCi 51Cr (CJS IP, sp. act. 1 mCi/mol., Radiochemical Centre, Amersham) for 1 h at 20°C. The targets were then washed once by centrifugation in 1640-HEPES-FCS, the sedimented cells resuspended in 10 ml of the same medium and reincubated for a further hour at 20°C. The cells were then washed twice, and the concentration adjusted to 5 x 104/ml or 105/ml for CMC assays.
CMC assay.-One hundred jtl of effector cells were mixed with 100 ,ul of the appropriate targets in microplates with 96 roundbottomed wells (M24ART, Sterilin). Each effector: target combination was tested in triplicate, at a ratio of 50:1 or, for the calculation of lytic units (LU) at ratios of 40, 20 and 10:1.
Blocking of CMC by "cold" targets was performed by adding 100 ,A of cultured lymphocytes and 50 ,ul of unlabelled target cells (2 x 105/ml) to each microplate well. The plates were spun at 60 q, incubated for 30 min at 37°C and 50 I,l of 5lCr-labelled K562 targets (2 x 104/ml) then added, giving a blocker: target-cell ratio of 10:1.
CMC assays were incubated at 37°C for 6 h in a humidified Gas-Pak 150 jar, then spun at 60 g for 5 min, and supernatanlts harvested with a SKATRON/Titertek supernatant harvester (FlowT Laboratories). 5ICr in the supernatants was detected on a Wallac DECEM GTL 300-500 gamma scintillation counter.
Percentage cytotoxicity (0o CMC) wras calculated from: E -S/T -S x 100, where E = experimental 51Cr release in the presence of lymphocytes, S = spontaneous 5 ICr released by target cells alone, and T = total 51Cr released by adding 20% Triton x 100 and freeze-thawing x 3.
Lytic units (LU) were calculated from slopes of 00 CMC against effector: target (E: T) ratio. 
RESULTS
Stimulation of CMC by acute leukaemnias
Previous results showed that both unprimed and in vivo-primed remission lymphocytes from leukaemia patients receiving immunotherapy developed CMC to CCL after in vitro stimulation with allogeneic leukaemia cells (Taylor et al., 1979) . This was investigated in greater detail as follows. Blocking of CMC by acute leukaemias The lymphocytes stimulated in the above experiments with allogeneic leukaemias or with allogeneic lymphocytes were tested for CMC on K562 targets in the presence of unlabelled homologous leukaemias or K562. CMC was partially blocked by AL-48 and almost completely blocked by K562 (Fig. 4) Fig. 5 with the response by an unprimed patient. In all tests no CMC was detected on autologous lymphocytes, and with one exception CMC was positive on allogeneic lymphocyte targets in lymphocytes stimulated in MLC.
Responses by the normal donors were similar to those of patient EH in that (1 (Zarling et al., 1976; Sondel et al., 1976; Lee & Oliver, 1978) , and it has been implied (Lee & Oliver, 1978 ) that lymphocytes of B-cell origin are necessary to induce antileukaemic CMC. B-lymphloid cell-lines also stimulate strong NK-like CMC in vitro . The induction of anti-leukaemic CMC in normal allogeneic and remission autologous leukaemia lymphocytes using both B and T co-stimulating cells was investigated. In Fig. 6 AL-51 also stimulated greater CMC on CCL targets than was found in unstimulated GR lymphocytes. On K562 this increased from 10% in unstimulated lymphocytes to 21% in autologous AL-51 stimulated lymphocytes. This amounted to 160/ of the amplification of NK-like CMC on K562 induced by allogeneic Daudi and CCRF-CEM.
The role of "conditioned" medium
In view of the ability of allogencic leukaemias to stimulate CMC to CCL, the possibility that conditioning factors were released into the culture medium wlhich could bring about this amplification was investigated. Lymphocytes from a normal donor (A) were cultured alone, with Xirradiated allogeneic lymphocytes (B) (AL-49 or AL-49 + B) for 6 days. The cultures were centrifuged to sediment the cells, and the media removed and filtered through 0 22 ,um Millipore filters. Fresh lymphocytes from A and B were then incubated with these media, alone or with irradiated AL-49. Control medium was fresh ] 640-AB. After 6 days in culture, the lymphocytes were harvested and assayed for CMC on AL-49 and K562 (Table III) Harris et al., 1978) developed strong CMC to immunizing leukaemia cells only when subjected to in vitro incubation with leukaemia cells (Taylor et al., 1976) . That prior in vivo immunization was essential was apparent, since normal and remission acute leukaemic lymphocytes from nonimmunized subjects failed to develop strong anti-leukaem-ic CMC under the same incubation conditions. (Taylor et al., 1976 (Taylor et al., , 1979 .
In this paper these investigations have been carried fuLrther. (1975) using the T-cell line HSB2, using the MOLT 4 T-cell line showed their ability to amplify NKlike CMC, whereas the proliferative stimulus was very low. The CEM leukaemic T-cell line used in this study was also capable of augmenting NK-like CMC, as were autologous leukaemia cells. Seeley & Golub (1978) , who demonstrated augmented NK-like CMC in human MLC, showed that it appeared before peak CTL responses. Callewaert et al. (1978) used BrdU to eliminate proliferating (T?) cells in MLC, and showed that allo-specific CML was reduced, but NK-like CMC was not. Taken together, these results suggest that NK-like CMC may be amplified in mixed leucocyte cultures both by defined (i.e., alloantigenic) and undefined stimulation.
The resistance of the acute leukaemias to NK-like CMC contrasts markedly with the susceptibility of CCL. Most of the CCL susceptible to NK-CMC have been derived from leukaemias , whereas those derived from normal B cells by transformation with EB virus and mitogen-transformed lymphocytes (Rosenberg et al., 1974; Seeley & Golub, 1978) are largely resistant.
The capacity of leukaemias to block CMC on K562 suggests that they may bind NK-like effector cells without undergoing lysis. However, one leukaemia exerted greater blocking, the greater the amplification of NK-like CMC. Since the competitor: target ratio was constant the increasing efficiency of blocking may have been related to the number or state of activation of the NK-like cells, and their affinity for leukaemia cells. Alternatively it could be that blocking is related to the efficiency of leukaemia cells to absorb endogenous conditioning factors (interferon?) responsible for NK-like activity. Thus, Trinchieri et al. (1978b) observed that interferon-untreated cold competitor cells inhibited interferon-amplified NK-CMC, whereas interferon-treated competitor cells did not.
The capacity of lymphocytes from only the primed patients to develop strong anti-leukaemic CMC contrasts with similar levels of NK-like CMC in response to an allogeneic leukaemia in primed and unprimed individuals. Nylon-wool fractionation before stimulation with leukaemia cells marginally increased NK-like CMC in the primed patient, but slightly reduced anti-leukaemic CMC. Both types of lytic activity were generated in the nylonnon-adherent fractions, but whether this means that NK-like CMC in primed lymphocytes involves the same population as the anti-leukaemic killer cells remains to be determined. Clearly to accommodate this, "primed" NK-like cells would have to differ qualitatively from those stimulated by leukaemia cells in unprimed individuals.
A number of studies have shown that CMC to autologous and HLA-identical leukaemias can be generated in lymphocytes stimulated with allogeneic lymphoid cells, with or without the appropriate leukaemia (Zarling et al., 1976 (Zarling et al., , 1978 Sondel et al., 1976; Lee & Oliver, 1978) . One interpretation of these findings is that the CMC generated by allogeneic cells is NK-like. Zarling's (1978) data using pooled stimulating lymphocytes, without leukaemia cells, suggests that stimulation with a patient's leukaemia may not be mandatory. In addition NK cells may be stimulated by interferon to become cytotoxic to leukaemias (Zarling et al., 1979) . In the present study the induction of CMC to allogeneic leukaemias by mixedcell stimulation did not cause the marked increase in NK-like CMC on CCL which might have been expected had a single type of cytotoxic cell been responsible for both phenomena. However, mixed-cell stimulation might induce qualitatively different NK-like lysis, both on CCL and leukaemia-cells. In the case of the autologous leukaemia, the most plausible explanation is that a specifically antileukaemic cytotoxic population is amplified.
Conditioning factors released in various mixed leucocyte cultures were able to amplify NK-mediated lysis of K562 by unstimulated lymphocytes, and also mildly enhance the killing capacity of leukaemiacell-stimulated lymphocytes on leukaemia cells. The role of interferon in augmenting NK-like cell-mediated lysis (Trinchieri et al., 1978b; Zarling et al., 1979; Moore & Potter, 1980) may be relevant to these observations. Endogenous interferon is induced in mixed lymphocyte cultures (Gifford et al., 1971) and in mixtures of 13 lymphocytes and tumour cells within a few hours of culture (Trinchieri et al., 1978a) . The high levels of NK-like CMC found in lymphocyte cultures stimulated with leukaemia cells could have been due to either endogenous interferon or factor(s) with similar biological properties. Factor(s) produced by alloantigenic stimulation in vitro (killer-cell helper factor) (Orosz & Finke, 1978; Sopori et al., 1978) and exogenous interferon can enhance cytotoxic T-cell activity (Heron et al., 1976) and recent evidence suggests at least one may be inseparable, biochemically, from interferon (Simon et al., 1979) .
